- Oops!Something went wrong.Please try again later.
Shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) traded at a new 52-week high today of $34.80. Approximately 5.5 million shares have changed hands today, as compared to an average 30-day volume of 3.9 million shares.
Xenon Pharmaceuticals Inc. is currently priced 47.7% above its average consensus analyst price target of $17.01.
Over the past year, Xenon Pharmaceuticals Inc. has traded in a range of $9.32 to $34.80 and is now at $32.54, 249% above that low.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including the rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901 and XEN496 for Epilepsy, XEN007 for Orphan neurological, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out through Canada.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Image Sourced from Pixabay
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.